CORRECTION OF SOME SIDE EFFECTS TO ANTI-TUBERCULOSIS THERAPY IN MODERN CONDITIONS
DOI:
https://doi.org/10.34287/MMT.2(53).2022.4Abstract
Introduction. Tuberculosis has not been eradicated in any country in the world. Chemotherapy plays a leading role in this fight. In the last two decades, the level of chemoresistant tuberculosis has increased significantly, contributing to an increase in the total number of side effects, often severe and widespread.
The aim of the study. Improving the effectiveness of treatment and quality of life of TB patients. This is based on scientific substantiation and development of methods for drug correction of toxic side effects of anti-TB therapy.
Materials and methods. 818 cases of complications from the use of anti-TB therapy were analyzed among patients treated at Zaporizhzhia Regional Clinical TB Dispensary between 2012 and 2016. Side effects increased over these years, due to an increased attention to pharmacovigilance.
Results. During the treatment of patients with pulmonary TB with preserved sensitivity to anti-TB therapy, side effects occurred in 48.8% of cases and in chemoresistant forms 51.2%. Patients with resistant forms of the process which were assigned to the 4th category of treatment predominated with complications of anti-TB therapy. Their percentage was 55.1%, which was 10.2% more than patients with preserved sensitivity. The structure of side effects was dominated by hepatotoxic reactions (36.0%) which were most often (28.0%) associated with the use of pyrazinamide and later returned to normal from the use of ademethionine. In total, the use of pyrazinamide resulted in 40.4% of cases of side effects.
Conclusions. The course of ademethionine helps to normalize clinical and laboratory parameters, regression of symptoms of toxic liver disease and improves the quality of life of patients with chemoresistant tuberculosis with toxic side effects of anti-TB therapy, which significantly reduces the length of hospital stay and increases treatment efficiency with compliance.
References
Byalik ІB, Cherenko SА, Petrenko VM et al. Reserves for improvement of polychemotherapy results in patients with ineffectively treated previously and chronic destructive multidrug-resistant pulmonary tuberculosis. Ukrainian Pulmonology Journal. 2010; 1: 43-46.
Velikaya OV, Akulova AV. Assessment of the quality of life of women patients with pulmonary tuberculosis using the SF-36 questionnaire. Nauchnye vedomosti. 2015; 16 (213): 110-115.
Gubergrits NB, Fomenko PG, Golubova OA et al. «Fatal chain» and ademetionine. Modern Gastroenterology. 2014; 4: 106-120.
Denisov OS. Influencing of donors of nitric oxide on intensity of synthesis of no in patients whith the first diagnosed destructive pulmonary tuberculosis during realization of an intensive phase of a chemotherapy. Ukrainian Chemothrapeutic Journal. 2010; 1-2 (23): 40-42.
Aniskina EA, Makarov II, Strakhov KA et al. Study of quality of life of patients with pulmonary tuberculosis. Medicinskaya ekologiya. 2012; 4: 58-62.
Kolpakova TA. The problem of comorbidity in the clinic of lung tuberculosis. Byulleten’ Vostochno-Sibirskogo nauchnogo centra SO RAMN. 2011; 2 (78): 48-51.
Melnyk VM, Novozhilova IA, Matusevich VG et al. The effectiveness of treatment of patients with newly detected tuberculosis and factors, worsening it nowadays. Ukrainian Pulmonology Journal. 2008; 2: 55-59.
Petrenko VI, Protsyuk RG. The problem of tuberculosis in Ukraine. Tuberculosis, Lung Diseases, HIV Infection. 2015; 2 (21): 16-29.
Pyatnochka IT, Kornaha SI, Thoryk NV. About attitude to the treatment of TB patients. Tuberculosis, Lung Diseases, HIV Infection. 2015; 1: 108-111.
Snegovoy AV, Manzyuk LV. Efficacy of Heptral® in the treatment of hepatic toxicity induced by cytostatic chemotherapy. Opukholi zhenskoj reproduktivnoj sistemy. 2010; 2: 47-52.
Feshchenko YuI, Litvinenko NA, Grankina NV et al. Treatment of patients with multidrugresistant and extensively drug resistant tuberculosis depending on the composition of individualized regimens: immediate and longterm results. Tuberculosis, Lung Diseases, HIV Infection. 2021; 4 (47): 7-15. doi:10.30978/TB-2021-4-7.
World Health Organization (WHO). Global tuberculosis report 2019. Geneva: WHO; 2020. - P. 283.
